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Abstract:  In  the  present  work,  we  investigated  the  effect  of  non-steroidal  
anti-inflammatory  drugs  (NSAIDs)  on  the  monophenolase  and  diphenolase  activity  of 
mushroom tyrosinase. The results showed that diflunisal and indomethacin inhibited both 
monophenolase and diphenolase activity. For monophenolase activity, the lag time was 
extended in the presence of diflunisal. In the presence of indomethacin, the lag time did not 
change. IC50 values of monophenolase activity were estimated to be 0.112 mM (diflunisal) 
and 1.78 mM (indomethacin). Kinetic studies of monophenolase activity revealed that both 
diflunisal and indomethacin were non-competitive inhibitors. For diphenolase activity, IC50 
values  were  estimated  to  be  0.197  mM  (diflunisal)  and  0.509  mM  (indomethacin). 
Diflunisal and indomethacin were also found to be non-competitive diphenolase inhibitors. 
Keywords: tyrosinase; monophenolase; diphenolase; NSAIDs (non-steroidal anti-inflammatory 
drugs); diflunisal; indomethacin 
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1. Introduction 
Tyrosinase  (monophenol  monooxygenase;  polyphenol  oxidase;  catechol  oxidase;  and  oxygen 
oxidoreductase; E.C. 1.14.18.1) is a copper-containing enzyme, responsible for the formation of the 
melanin of skin, hair, and eye [1,2]. In addition, tyrosinase is found in animals, plants, fungi and 
microorganisms [1].  
Tyrosinase catalyzes two different chemical reactions: the hydroxylation of monophenol and the 
oxidation of O-diphenol to the corresponding O-quinone [3–5]. Recently, the crystallographic structure 
of tyrosinase was reported, and this enzyme has a catalytic center formed by dinuclear copper [4,6,7]. 
Skin pigmentation results from melanin synthesis by melanocytes and is caused by exposure to UV 
radiation. Melanin plays an important role in the prevention of UV-induced skin injury and is a major 
determinant of skin color [8,9]. However, tyrosinase enhances melanogenesis, which leads to many 
hyperpigmentation disorders such as melasma, postinflammatory pigmentation, and solar lentigo, and 
these symptoms become prominent with aging. Moreover, tyrosinase is responsible for the undesired 
browning of fruits and vegetables during post-harvest storage [10,11]. Therefore, studies of inhibitory 
mechanisms of tyrosinase inhibitors are important in preventing enzymatic browning of vegetables and 
hyperpigmentation disorders. A huge number of tyrosinase inhibitors have been studied to date. For 
example, various aromatic carboxylic acids are known to be potent inhibitors of tyrosinase [12,13]. 
Non-steroidal  anti-inflammatory  drugs  (NSAIDs)  are  known  to  act  by  directly  suppressing  the 
activity  of  cyclooxygenase  (COX),  the  key  enzyme  catalyzing  the  biosynthesis  of  prostaglandins, 
which induce inflammation. Therefore, NSAIDs are generally used to treat pain, inflammation and 
fever. Moreover, some researchers reported that NSAIDs are able to prevent the development of cancer 
of the colon, breast, stomach and lung [14–17]. These biological effects of NSAIDs are the result of 
their ability to induce apoptosis and cell cycle arrest [18,19]. Acetylsalicylic acid is one of the most 
well studied NSAIDs, and has been shown to be effective as an antiplatelet drug in preventing heart 
attacks, stroke and cerebral thrombosis [20–22].  
Recently, we found that acetylsalicylic acid (ASA) down-regulates tyrosinase protein expression 
and inhibits melanogenesis on B16F1 melanoma cells [23], and we reported that mefenamic acid and 
diclofenac also inhibit melanogenesis [24]. However, no reports on the anti-melanogenic effect of 
NSAIDs have been published. Therefore, it is important to investigate the effects of other NSAIDs on 
melanogenesis. Consequently, we sought to investigate the inhibitory effect of NSAIDs (acetylsalicylic 
acid  ASA,  mefenamic  acid,  diclofenac,  diflunisal,  ibuprofen  and  indomethacin)  (Figure  1)  on  the 
activity of mushroom tyrosinase. These NSAIDs are well-known non-selective COX inhibitors [25].  
2. Results and Discussion  
2.1. Effects of NSAIDs on the Monophenolase and Diphenolase Activity of Mushroom Tyrosinase 
To clarify the effects of NSAIDs on mushroom tyrosinase activity, we first performed a tyrosinase 
assay to investigate monophenolase activity by using  L-tyrosine as a substrate. As summarized in 
Table 1, ASA, ibuprofen and mefenamic acid did not inhibit monophenolase activity of tyrosinase. 
Diclofenac  and  mefenamic  acid  slightly  inhibited  tyrosinase  activity  (25%  inhibition  at  the 
concentration of 4 mM diclofenac and 9% inhibition at 1 mM mefenamic acid, respectively). ASA did Int. J. Mol. Sci. 2011, 12                       
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not show any inhibition. On the other hand, indomethacin showed inhibitory activity (IC50 = 1.78 mM), 
and furthermore diflunisal significantly inhibited tyrosinase activity (IC50 = 0.112 mM). 
Figure 1. Chemical structure of NSAIDs used in this study. 
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Table 1. IC50 values of NSAIDs on monophenolase activity and diphenolase activity. 
IC50 (mM) 
Compound  Monophenolase Activity  Diphenolase Activity 
Acetylsalicylic acid  >4  >4 
Diclofenac  >4  7.1 
Diflunisal  0.112  0.197 
Ibuprofen  >4  >1 
Indomethacin  1.78  0.509 
Mefenamic acid  >1  >0.2 
To investigate the effect of NSAIDs on diphenolase activity, we performed a tyrosinase assay by 
using L-DOPA as a substrate. ASA and ibuprofen did not inhibit diphenolase activity of mushroom 
tyrosinase  (Table  1)  (−6%  inhibition  at  4  mM  ASA  and  8%  inhibition  at  1  mM  ibuprofen, 
respectively). Mefenamic acid slightly inhibited diphenolase activity at the concentration of 0.2 mM. 
Diclofenac slightly inhibited diphenolase activity (IC50 = 7.1 mM). Both diflunisal and indomethacin 
inhibited diphenolase activity. The IC50 values of these compounds were estimated at 0.197 mM and 
0.509 mM, respectively. Diflunisal inhibited monophenolase activity more than diphenolase activity. 
For indomethacin, the IC50 value of the monophenolase activity was about three times larger than 
diphenolase activity. 
In this study, we used non-selective COX inhibitors [25]. ASA, ibuprofen and mefenamic acid did 
not  inhibit  monophenolase  or  diphenolase  activity.  On  the  other  hand,  diclofenac,  diflunisal  and 
indomethacin inhibited both catalytic activities. These results imply that the inhibitory effect of COX 
activity of NSAIDs was not related to tyrosinase activity. Int. J. Mol. Sci. 2011, 12                       
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2.2. The Mechanism of Inhibition on Monophenolase Activity of Mushroom Tyrosinase by Diflunisal 
and Indomethacin 
Several  NSAIDs  inhibit  mushroom  tyrosinase  activity.  We  therefore investigated  the  inhibitory 
mechanism of diflunisal and indomethacin on mushroom tyrosinase. When the monophenolase activity 
of  mushroom  tyrosinase  was  assayed  using  L-tyrosine  as  a  substrate,  a  lag  time,  characteristic  of 
monophenolase activity, was observed simultaneously with the appearance of the first stable product, 
dopachrome, which was derived from oxidative hydroxylation of monophenolic substrates [25,26]. 
The kinetic course of the inhibition of monophenolase activity by different concentrations of diflunisal 
is shown in Figure 2. The results showed that diflunisal had an inhibitory effect on monophenolase 
activity and the system reached a steady state after the lag time. The lag time was extended in the 
presence  of  diflunisal  in  a  dose-dependent  manner.  On  the  other  hand,  despite  the  fact  that 
indomethacin inhibits the kinetic courses of monophenolase activity, the lag time did not change in the 
presence of inhibitor (Figure 3). In the presence of diflunisal, monophenolase activity of mushroom 
tyrosinase was significantly inhibited (approximately 45 ±  13% at 0.25 mM, 34 ±  7% at 0.5 mM,  
27  ±   6%  at  0.75  mM  and  20  ±   8%  at  1.0  mM)  (Figure  4A).  Indomethacin  also  inhibited 
monophenolase activity in a dose-dependent manner (approximately 84 ±  4% at 0.25 mM, 72 ±  5% at 
0.5 mM, 66 ±  6% at 0.75 mM and 60 ±  4% at 1.0 mM) (Figure 4B). 
Figure 2. (A) Progress curves for the inhibition of monophenolase activity of tyrosinase by 
diflunisal. L-tyrosine was incubated with mushroom tyrosinase with or without diflunisal as 
described in the Experimental Section. The concentrations of diflunisal for curves 0–5 were 
0 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1.0 mM, respectively; (B) Relationship of the lag 
time with the concentration of diflunisal. 
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We  also  investigated  the  inhibition  type  of  diflunisal  and  indomethacin  on  the  monophenolase 
activity of mushroom tyrosinase. Lineweaver-Burk plots for the inhibition of monophenolase activity 
by diflunisal were obtained (Figure 5A). The plots of 1/Vss versus 1/[S] gave a family of straight lines 
with  different  slopes  which  intersected  one  another  on  the  X-axis,  indicating  that  diflunisal  is  a  Int. J. Mol. Sci. 2011, 12                       
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non-competitive inhibitor. The equilibrium constants for inhibitor binding with the free enzyme and 
the enzyme-substrate complex, KI and KIS, were obtained from the secondary plot (Figure 5B) as  
0.11 mM and 0.11 mM. The kinetics of the enzyme in the presence of indomethacin are shown in 
Figure 6. The results showed that indomethacin was also a non-competitive inhibitor. The inhibitor 
constants (KI and KIS) were estimated to be 0.75 mM and 0.75 mM, respectively. 
Figure 3. (A) Progress curves for the inhibition of monophenolase activity of tyrosinase by 
indomethacin.  L-tyrosine  was  incubated  with  mushroom  tyrosinase  with  or  without 
indomethacin  as  described  in  the  Experimental  Section.  The  concentrations  of 
indomethacin  for curves  0–5 were 0 mM, 0.25  mM, 0.5 mM, 0.75  mM  and  1.0  mM, 
respectively; (B) Relationship of the lag time with the concentration of indomethacin. 
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Figure 4. Relationship of the steady-state rate with the concentration of diflunisal (A) and 
indomethacin  (B)  L-tyrosine  was  incubated  with  mushroom  tyrosinase  with  or  without 
diflunisal or indomethacin as described in Experimental Section. 
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Figure  5.  Determination  of  inhibitory  type  and  inhibition  constants  of  diflunisal  on 
monophenolase activity of mushroom tyrosinase. (A) Lineweaver-Burk plots for inhibition 
of diflunisal on monophenolase activity. The concentrations of diflunisal for curves 1–5 
were 0 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1.0 mM, respectively; (B) The plots of slope 
versus the concentration of diflunisal. 
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Figure 6. Determination of inhibitory type and inhibition constants of indomethacin on 
monophenolase activity of mushroom tyrosinase. (A) Lineweaver-Burk plots for inhibition 
of  indomethacin  on  monophenolase  activity.  The  concentrations  of  indomethacin  for 
curves 1–5 were 0 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1.0 mM, respectively; (B) The 
plots of slope versus the concentration of indomethacin. 
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2.3. The Mechanism of Inhibition on Diphenolase Activity of Mushroom Tyrosinase by Diflunisal and 
Indomethacin 
We also investigated the effect of diflunisal and indomethacin on diphenolase activity by using  
L-DOPA as a substrate. As shown in Figure 7, the result showed that both diflunisal and indomethacin 
inhibit  the  diphenolase  activity  in  a  dose-dependent  manner.  The  IC50  values  of  diflunisal  and 
indomethacin are shown in Table 1. In the presence of diflunisal, diphenolase activity of mushroom 
tyrosinase was clearly inhibited (approximately 77 ±  1% at 0.05 mM, 63 ±  2% at 0.1 mM, 49 ±  4% at 
0.2  mM,  32  ±   2%  at  0.5  mM  and  20  ±   2%  at  1.0  mM)  (Figure  7).  Indomethacin  also  inhibited 
diphenolase activity in a dose-dependent manner (approximately 89 ±  4% at 0.05 mM, 82 ±  3% at  
0.1 mM, 70 ±  3% at 0.2 mM, 50 ±  3% at 0.5 mM and 32 ±  2% at 1.0 mM).  
Figure 7. Effects of diflunisal (■) and indomethacin (▲) on the diphenolase activity of 
mushroom tyrosinase. L-DOPA was incubated with mushroom tyrosinase with or without 
diflunisal of indomethacin as described in the Experimental Section. 
0
20
40
60
80
100
120
0.2 0.4 0.6 0.8 1.0 1.2 0.0
D
i
p
h
e
n
o
l
a
s
e
 
a
c
t
i
v
i
t
y
 
(
%
)
[I] (mM)
0
20
40
60
80
100
120
0.2 0.4 0.6 0.8 1.0 1.2 0.0
D
i
p
h
e
n
o
l
a
s
e
 
a
c
t
i
v
i
t
y
 
(
%
)
[I] (mM)  
We studied the inhibitory mechanism of diflunisal and indomethacin on diphenolase activity of 
mushroom tyrosinase. Lineweaver-Burk plots for inhibition of diflunisal are shown in Figure 8A. The 
results showed that diflunisal was a non-competitive inhibitor since the plots of 1/v versus 1/[S] gave a 
family of straight lines with different slopes, which intersected one another in the X-axis. The inhibitor 
constants (KI and KIS) were estimated to be 0.19 mM and 0.19 mM, respectively. The kinetics of the 
enzyme in the presence of indomethacin is shown in Figure 8B. The results showed that indomethacin 
also was a non-competitive diphenolase inhibitor. The inhibitor constants (KI and KIS) were estimated 
to be 2.42 mM and 2.42 mM, respectively.  Int. J. Mol. Sci. 2011, 12                       
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Figure 8. Determination of inhibitory type of diflunisal and indomethacin on diphenolase 
activity of mushroom tyrosinase. (A) Lineweaver-Burk plots for inhibition of diflunisal on 
diphenolase activity. The concentrations of diflunisal for curves 1–3 were 0.1, 0.2 and  
1.0  mM,  respectively;  (B)  Lineweaver-Burk  plots  for  inhibition  of  indomethacin  on 
diphenolase  activity.  The  concentration  of  indomethacin  for  curves  1–3  were  0.1,  0.2  
and  1.0  mM,  respectively.  The  results  showed  that  indomethacin  also  was  a  
non-competitive inhibitor. 
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3. Experimental Section 
Tyrosinase from mushroom was purchased from Sigma. Dimethylsulfoxide (DMSO), L-tyrosine,  
L-3,4-dihydroxyphenylalanine  (L-DOPA),  acetylsalicylic  acid  (ASA),  mefenamic  acid,  diclofenac, 
diflunisal and kojic acid were purchased from Sigma. Ibuprofen and indomethacin were purchased 
from Wako Pure Chemical. All NSAIDs and kojic acid used in the monophenolase and diphenolase 
activity assay were dissolved in DMSO. 
The monophenolase activity assay was performed with modification as reported by Chen et al. [27]. 
In this assay, L-tyrosine was used as substrate in the monophenolase activity assay. First, 300 μL of  
2.5  mM  L-tyrosine,  25  μL  of  DMSO  with  or  without  a  sample  chemical,  and  300  μL  of  0.1  M 
phosphate buffer (pH 6.8) were mixed. The mixture was preincubated at 37 C for 10 min before  
125  μL  of  1000  units/mL  mushroom  tyrosinase  in  aqueous  solution  added,  and  the  reaction  was 
performed at 37 C. Enzyme activity was monitored at 475 nm by a UV spectrophotometer (Shimadzu, 
UV-1700). The lag time was determined by extrapolation of the linear portion of the dopachrome 
accumulation curve to the abscissa axis.  
The  diphenolase  activity  assay  was  performed  as  previously  described  [28].  First,  300  μL  of  
2.5 mM 3,4-dihydroxyphenylalanine (L-DOPA) solution, 50 μL of DMSO with or without a sample 
chemical, and 1.1 mL of 0.1 M phosphate buffer (pH 6.8) were mixed. The mixture was preincubated 
at 25 C for 10 min before 50 μL of 1000 units/mL mushroom tyrosinase in aqueous solution was 
added, and the reaction was monitored at 475 nm. A control reaction was conducted in DMSO alone. 
The percentage of activity of tyrosinase was calculated as follows: 100 − [(A − B)/A ×  100], where A 
represents the difference in the absorbance of the control sample between an incubation time of 0.5 and Int. J. Mol. Sci. 2011, 12                       
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1.0  min,  and  B  represents  the  difference  in  the  absorbance  of  the  test  sample  over  the  same  
incubation period.  
The inhibition type of NSAIDs on the monophenolase and diphenolase activity was determined by 
the Lineweaver-Burk plots and the inhibition constants were determined from secondary plots of the 
apparent Km/Vmax versus the concentration of the inhibitor. 
4. Conclusions  
In this study, we investigated the inhibitory effect of NSAIDs on mushroom tyrosinase. The results 
showed that diflunisal and indomethacin significantly inhibit monophenolase and diphenolase activity. 
As summarized in Table 2, the IC50 value of diflunisal on monophenolase activity was smaller than 
diphenolase activity. On the other hand, the IC50 value of indomethacin on monophenolase activity 
was  about  three  times  as  large  as  diphenolase  activity.  The  kinetic  studies  showed  that  both 
compounds were non-competitive inhibitors. We also estimated lag time on monophenolase assay. 
From the results, diflunisal lengthens the lag period. On the other hand, indomethacin did not lengthen 
the lag period. Li et al. described that if an inhibitor is combined with free enzyme, it lengthens the lag 
period.  If  an  inhibitor  is  combined  with  ES  (enzyme-substrate  complex)  ,  it  only  decreases  the  
steady-state rate but does not lengthen the lag period [29].  
Table 2. Inhibition constants of diflunisal and indomethacin with mushroom tyrosinase. 
Constant    Diflunisal  Indomethacin 
IC50  Monophenolase  0.112 mM  1.780 mM 
  Diphenolase  0.197 mM  0.509 mM 
Inhibition type    Non-competitive  Non-competitive 
KI  Monophenolase  0.11 mM  0.75 mM 
  Diphenolase  0.19 mM  2.42 mM 
Our results showed diflunisal is the most effective tyrosinase inhibit or out of six NSAIDs in the 
present study. Interestingly, diflunisal is a chemical analog of ASA.  However, ASA did not inhibit 
either monophenolase or diphenolase activity. Further studies of other NSAIDs on tyrosinase activity 
and the depigmenting effect of NSAIDs are very important. These compounds may be useful inhibitors 
of tyrosinase and they might lead to an effective treatment of hyperpigmentation disorders.  
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